Skip to main content
Premium Trial:

Request an Annual Quote

Galapagos Licenses Asthma and Allergy Targets, Provides Research to GSK

NEW YORK, Jan. 5 (GenomeWeb News) - Galapagos has licensed asthma and allergy drug targets to GlaxoSmithKline and will identify further targets for the drug maker, the Mechelen, Belgium-based company said today.

 

Under the agreement, GSK licensed a number of drug targets discovered by Galapagos using its siRNA-based adenovirus technology. In addition, Galapagos' reagents and services division, Galadeno, will use its SilenceSelect gene knock-down platform to discover and validate further targets for asthma and inflammatory diseases for GSK for three years.

 

GSK will pay Galapagos an upfront fee and provide research funding. Galapagos will also receive milestone payments for targets that GSK chooses to develop.

The Scan

Genetic Tests Lead to Potential Prognostic Variants in Dutch Children With Dilated Cardiomyopathy

Researchers in Circulation: Genomic and Precision Medicine found that the presence of pathogenic or likely pathogenic variants was linked to increased risk of death and poorer outcomes in children with pediatric dilated cardiomyopathy.

Fragile X Syndrome Mutations Found With Comprehensive Testing Method

Researchers in Clinical Chemistry found fragile X syndrome expansions and other FMR1 mutations with ties to the intellectual disability condition using a long-range PCR and long-read sequencing approach.

Team Presents Strategy for Speedy Species Detection in Metagenomic Sequence Data

A computational approach presented in PLOS Computational Biology produced fewer false-positive species identifications in simulated and authentic metagenomic sequences.

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.